Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 深圳市新产业生物医学工程股份有限公司成立于1995年12月15日，是专业从事研发、生产、销售“体外诊断仪器及试剂”的国家级高新技术企业，注册资本37,040万元人民币。公司自成立以来，一直专注于化学发光免疫分析领域的研究，经过15年的潜心努力，于2010年2月将中国第一台全自动化学发光免疫分析仪及配套试剂成功推上市场。通过不断的技术创新，公司于2016年将智能化的“模块化生化免疫分析系统”成功推上市场，丰富了公司产品线。2017年7月，新产业生物通过美国FDA510(k)审核，获得准入许可，正式成为中国第一家获得美国FDA准入的化学发光厂家。2018年，新产业生物成功发布全球最快全自动化学发光免疫分析系统MAGLUMI?X8。2019年7月，新产业生物自主研发的丙型肝炎化学发光产品成功通过欧盟CEListA认证，成为中国第一家丙肝试剂荣获欧盟CE最高认证的化学发光厂家。 新产业生物公司是中国第一家采用最先进的“纳米免疫磁性微珠”作为系统的关键分离材料的公司、中国第一家采用目前该领域最先进的“人工合成的小分子有机化合物”代替传统的酶作为发光标记物的公司、中国第一家应用直接化学发光免疫分析技术并实现批量生产全自动化学发光免疫分析仪器及配套试剂的公司。公司的研发成果，填补了国内在体外诊断领域的空白，打破了该领域长期被国外厂家产品垄断和技术封锁的局面，已成为中国化学发光免疫定量分析领域的领导者。 公司主营业务：全自动化学发光免疫分析仪器及配套化学发光试剂：MAGLUMI?800、MAGLUMI?1000、MAGLUMI?2000、MAGLUMI?2000Plus、MAGLUMI?4000、MAGLUMI?4000Plus、MAGLUMI?X8全自动化学发光免疫分析仪，配套试剂122项：甲状腺功能、性激素、肿瘤标志物、心肌标志物、术前八项、优生优育、糖代谢、骨代谢、肝纤维化、炎症监测等检测项目；全实验室自动化流水线及配套试剂：SATLAS-TCA、PAM-MAGLUMI?X8-LST008AS；模块化生化免疫分析系统：Biolumi?8000及配套试剂；全自动生化分析仪器：Biossays?BC1200、Biossays?BC2200及生化试剂：血脂、肝功能、肾功能、心肌酶谱等。 公司现有员工1700多人，其中博士、硕士及海外归国人士200多人。公司拥有试剂研发及生产中心、仪器研发及制造中心、营销中心等专业团队支持公司的快速发展。试剂研发及生产中心拥有9条试剂生产线，2019年坪山基地二期投产后试剂年产逐步提升至400万盒的产能；仪器研发及制造中心拥有年产2500台全自动化学发光分析仪和1500台全自动生化分析仪的产能；公司国内营销和服务网络已经覆盖到全国所有地区，公司正积极拓展海外市场，目前已与意大利、西班牙、法国、哥伦比亚等140多个国家和地区建立了合作关系。 公司一如既往践行我们的使命：以客户为中心，以市场为导向，通过持续不断的产品和技术创新，为人类生命健康事业不断创造价值。
Main Business 研发、生产及销售系列全自动化学发光免疫分析仪器及配套试剂。
Legal Representative 饶微
Top Executives
董事长：饶微
董事：饶微,翁鹤鸣,李旭,饶捷
独立董事：张清伟,王岱娜,伍前辉
Top 5 Shareholder
Shareholder name Nature Holding Date
西藏新产业投资管理有限公司流通A股26.88%31/03/2024
饶微限售股+流通A股13.77%31/03/2024
天津红杉聚业股权投资合伙企业（有限合伙）流通A股12.62%31/03/2024
香港中央结算有限公司流通A股3.25%31/03/2024
饶捷限售股+流通A股3.19%31/03/2024
Company Secretary 张蕾
Solicitors 北京国枫律师事务所
Auditors 大华会计师事务所（特殊普通合伙）
Tel No 0755-86540062
Fax No 0755-26654800
Website www.snibe.com
Email snibeinfo@snibe.net
Company Address
Register: 广东省深圳市坪山区坑梓街道金沙社区锦绣东路23号新产业生物大厦二十一层
Office: 广东省深圳市坪山区坑梓街道金沙社区锦绣东路23号新产业生物大厦二十一层
Listing Date 12/05/2020
Shares Capital
Shares Capital: 785,718,785
Total A Share: 785,718,785
Listed A Share: 698,373,139
Non-tradable A Share: 87,345,646
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 2.105
DPS(RMB)* ¥ 1.000
NBV Per Share(RMB)* ¥ 9.602
Market Capitalization(RMB) 54.354B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.